West-pharma-East - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,587,972 | 1,443,863 | 1,493,586 | 1,378,220 | 1,438,723 | 1,337,703 | 1,339,173 | 1,258,909 |
| Profit before tax | - | - | 57,704 | - | - | 125,988 | 172,751 | 109,219 |
| Net profit | 136,611 | 44,475 | 46,331 | 93,846 | 113,163 | 105,165 | 140,383 | 90,659 |
| Equity | 920,969 | 884,216 | 844,550 | 807,807 | 618,729 | 500,401 | 553,005 | 562,253 |
| Liabilities | 314,779 | 315,198 | 237,975 | 423,350 | 459,528 | 441,373 | 231,206 | 154,025 |
| Non-current assets | 129,366 | 243,032 | 171,660 | 130,315 | 98,600 | 58,849 | 33,846 | 6,685 |
| Current assets | 1,103,175 | 948,310 | 903,506 | 1,095,653 | 974,787 | 877,006 | 744,121 | 703,923 |
| Total assets | 1,232,541 | 1,191,342 | 1,075,166 | 1,225,968 | 1,073,387 | 935,855 | 777,967 | 710,608 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 248,530 | 256,955 | 266,991 |
| Social insurance contributions | - | - | - | - | - | 24,357 | 33,670 | 27,715 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +4.1% | -9.1% | +3.4% | -7.7% | +4.4% | -7.0% | +0.1% | -6.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 11.1% | 3.7% | 4.3% | 7.7% | 10.5% | 11.2% | 18.0% | 12.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 14.8% | 5.0% | 5.5% | 11.6% | 18.3% | 21.0% | 25.4% | 16.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 8.6% | 3.1% | 3.1% | 6.8% | 7.9% | 7.9% | 10.5% | 7.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 3.9% | - | - | 9.4% | 12.9% | 8.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.4 | 0.3 | 0.5 | 0.7 | 0.9 | 0.4 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 317,594 | 196,891 | 284,493 | 243,214 | 243,163 | 263,156 | 267,835 | 302,136 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
West-pharma-East - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-10-18 | 2021-10-19 | 68.06 |
West-pharma-East - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-06-28 | 2026-06-30 | 3325.0 |
| 2025-02-23 | 2025-02-25 | 1.1 |
| 2025-02-22 | 2025-02-22 | 0.8 |
| 2024-11-28 | 2024-12-01 | 2.4 |
| 2024-11-17 | 2024-11-25 | 2.4 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
West-pharma-East, UAB, a Private Limited Liability Company (code 301744827), operates in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €1.26M, down 6.0% year on year and 5.9% over two years. Net profit for 2025 was €90.7K, compared with €140.4K in 2024 and €105.2K in 2023, showing a weaker profit level than the prior two years. The 2025 net profit margin was 7.2%, versus 10.5% in 2024 and 7.9% in 2023. Profit before tax amounted to €109.2K in 2025. The balance sheet remained solid, with total assets of €710.6K, equity of €562.3K and liabilities of €154.0K. Equity accounted for 79.1% of assets, and the debt-to-equity ratio was 0.27. Asset turnover stood at 1.77x, ROE at 16.1% and ROA at 12.8% in 2025. Revenue per employee was €314.7K and profit per employee was €22.7K, indicating relatively strong productivity.